BeiGene
BGNE
#881
Rank
C$30.08 B
Marketcap
$273.98
Share price
1.71%
Change (1 day)
5.47%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : C$4.56 B

According to BeiGene 's latest financial reports the company has C$4.56 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$C$4.69 B-21.12%
2022-12-31$C$5.94 B-23.36%
2021-12-31$C$7.76 B57.3%
2020-12-31$C$4.93 B289.04%
2019-12-31$C$1.26 B-46.98%
2018-12-31$C$2.39 B178.09%
2017-12-31$C$0.86 B81.39%
2016-12-31$C$0.47 B359.52%
2015-12-31$C$0.10 B245.33%
2014-12-31$C$29.88 M-172.54%
2013-12-31$-C$41.2 M

Net assets for similar companies or competitors

Company Net assets differencediff. Country
C$8.15 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.89 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA